59 results on '"Cainazzo, Mm"'
Search Results
2. Efficacia di rizatriptan in relazione alla presenza di allodinia cutanea in pazienti affetti da emicrania senz’aura. Risultati preliminari
- Author
-
Granella, F., Zucco, R., Ferrari, Anna, Cainazzo, Mm, Bonazzi, A., Sternieri, E., and Pini, Luigi Alberto
- Subjects
allodinia cutanea ,libertà dal dolore ,emicrania senz’aura ,rizatriptan - Published
- 2010
3. Management of patients with primary headache by headache centres improves quality of life
- Author
-
Granella, F., Bonazzi, A., Cainazzo, Mm, Castellari, A., Ferrari, Anna, Marzocchi, N., Morandi, C., Pini, Luigi Alberto, Sternieri, E., and Zucco, R.
- Subjects
quality of life ,disability ,primary headache - Published
- 2008
4. Experience with the drug information service of the university hospital of Modena
- Author
-
Ferrari, Anna, Sternieri, E, Pini, Luigi Alberto, Cainazzo, Mm, Leone, S, Pinetti, D, and Bertolini, A.
- Subjects
drug ,information ,service - Published
- 2005
5. ELECTRICAL STIMULATION OF EFFERENT VAGAL FIBRES PREVENTS IN REAL-TIME NUCLEAR-FACTOR-KB AND INFLAMMATORY CASCADE ACTIVATION AND PROLONGS SURVIVAL, IN HEMORRHAGIC SHOCK
- Author
-
Cainazzo, Mm, Altavilla, Domenica, Giuliani, D, Mioni, C, Leone, S, Bazzani, C, Marini, Herbert Ryan, Bigiani, A, Bertolini, A, Squadrito, Francesco, and Guarini, S.
- Published
- 2003
6. Serum concentrations of vitamin B12 and folate in chronic daily headache
- Author
-
Ferrari, Anna, Trenti, T, Casto, G, Gallesi, D, Cainazzo, Mm, Mellini, S, and Sternieri, E.
- Subjects
concentration ,chronic headache ,level ,vitamin B12 ,folate ,serum - Published
- 1999
7. I trattamenti farmacologici nelle disintossicazioni
- Author
-
Ferrari, Anna, Casto, G, Cainazzo, Mm, Cuzzola, D, and Pantaleoni, M.
- Subjects
tossicodipendenza ,farmaco ,metadone ,disintossicazione ,eroina - Published
- 1999
8. Adrenocorticotropin reverses vascular dysfunction and protects against splanchnic artery occlusion shock
- Author
-
Squadrito, F., Guarini, Salvatore, Altavilla, D., Squadrito, G., Campo, Gm, Arlotta, M., Quartarone, C., Saitta, A., Cucinotta, D., Bazzani, Carla, Cainazzo, Mm, Mioni, Chiara, Bertolini, Alfio, and Caputi, Ap
- Subjects
Male ,Splanchnic artery occlusion shock ,Vascular dysfunction ,ACTH(1–24) ,TNF-αlpha ,Tumor Necrosis Factor-alpha ,Blood Pressure ,Constriction, Pathologic ,In Vitro Techniques ,Intercellular Adhesion Molecule-1 ,Immunohistochemistry ,Rats ,Rats, Sprague-Dawley ,Adrenocorticotropic Hormone ,Papers ,Animals ,Endothelium, Vascular ,Splanchnic Circulation - Abstract
1. Tumour necrosis factor (TNF-alpha) is involved in the pathogenesis of splanchnic artery occlusion (SAO) shock. On the other hand, inhibition of TNF-alpha is an important component of the mechanism of action of melanocortins in reversing haemorrhagic shock. We therefore investigated the effects of the melanocortin peptide ACTH-(1 - 24) (adrenocorticotropin fragment 1 - 24) on the vascular failure induced by SAO shock. 2. SAO-shocked rats had a decreased survival rate (0% at 4 h of reperfusion, while sham-shocked rats survived for more than 4 h), enhanced serum TNF-alpha concentrations (755+/-81 U ml-1), decreased mean arterial blood pressure, leukopenia, and increased ileal leukocyte accumulation, as revealed by means of myeloperoxidase activity (MPO=9.4+/-1 U g-1 tissue). Moreover, aortic rings from shocked rats showed a marked hyporeactivity to phenylephrine (PE, 1 nM - 10 microM) (Emax and ED50 in shocked rats=7.16 mN mg-1 tissue and 120 nM, respectively; Emax and ED50 in sham-shocked rats=16.31 mN mg-1 tissue and 100 nM, respectively), reduced responsiveness to acetylcholine (ACh, 10 nM-10 microM) (Emax and ED50 in shocked rats=30% relaxation and 520 nM, respectively; Emax and ED50 in sham-shocked rats=82% relaxation and 510 nM, respectively) and increased staining for intercellular adhesion molecule-1 (ICAM-1). 3. ACTH-(1 - 24) [160 microg kg-1 intravenously (i.v.), 5 min after SAO] increased survival rate [SAO+ACTH-(1 - 24)=80% at 4 h of reperfusion], reversed hypotension, reduced serum TNF-alpha (55+/-13 U ml-1), ameliorated leukopenia, reduced ileal MPO (1.2+/-0.2 U g-1 tissue), restored the reactivity to PE, improved the responsiveness to ACh and blunted the enhanced immunostaining for ICAM-1 in the aorta. 4. Adrenalectomy only in part - but not significantly - reduced the ACTH-induced shock reversal, the survival rate of SAO+ACTH-(1 - 24) adrenalectomized rats being 60% at 4 h of reperfusion; and methylprednisolone (80 mg-1 i.v., 5 min after SAO) had a non-significant effect (10% survival) at 4 h of reperfusion. 5. The present data show that melanocortins are effective also in SAO shock, their effect being, at least in part, mediated by reduced production of TNF-alpha. Furthermore, they demonstrate, for the first time, that this inhibition is responsible for the adrenocorticotropin-induced reversal of vascular failure and leukocyte accumulation.
- Published
- 1999
9. A case of a GH-producing pituitary adenoma associated with a unilateral headache with autonomic signs.
- Author
-
Marzocchi N, Cainazzo MM, Catellani D, and Pini LA
- Abstract
A 66-year-old man suffered from a drug-resistant, leftsided headache with autonomic signs, triggered by the supine position. The acromegalic facies initially suggested a possible increase in basal plasma levels of GH, but routine haematological controls excluded abnormal values of GH. Cerebral and facial CT scan and MRI did not detect any alterations in the nasal sinuses, except for a mucous cyst. Surgical ablation of the cyst did not alleviate the pain. Further endocrinological tests demonstrated an increase of IGF-1 (somatomedin C), and another MRI scan of the sellar region confirmed the presence of a pituitary macroadenoma on the left paramedian side. After an initial improvement of the symptomatology due to trans-sphenoidal ablation of a benign GH-producing macroadenoma, the headache worsened again. Pain was well correlated with the increased plasma levels of IGF-1. The patient died suddenly for myocardial infarct. [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
10. Correction to: Monoclonal anti‑CGRP antibodies in post‑menopausal women: a real‑life study.
- Author
-
Guerzoni S, Baraldi C, Brovia D, Cainazzo MM, Castro FL, and Pani L
- Published
- 2023
- Full Text
- View/download PDF
11. Cluster Headache Genomewide Association Study and Meta-Analysis Identifies Eight Loci and Implicates Smoking as Causal Risk Factor.
- Author
-
Winsvold BS, Harder AVE, Ran C, Chalmer MA, Dalmasso MC, Ferkingstad E, Tripathi KP, Bacchelli E, Børte S, Fourier C, Petersen AS, Vijfhuizen LS, Magnusson SH, O'Connor E, Bjornsdottir G, Häppölä P, Wang YF, Callesen I, Kelderman T, Gallardo VJ, de Boer I, Olofsgård FJ, Heinze K, Lund N, Thomas LF, Hsu CL, Pirinen M, Hautakangas H, Ribasés M, Guerzoni S, Sivakumar P, Yip J, Heinze A, Küçükali F, Ostrowski SR, Pedersen OB, Kristoffersen ES, Martinsen AE, Artigas MS, Lagrata S, Cainazzo MM, Adebimpe J, Quinn O, Göbel C, Cirkel A, Volk AE, Heilmann-Heimbach S, Skogholt AH, Gabrielsen ME, Wilbrink LA, Danno D, Mehta D, Guðbjartsson DF, Rosendaal FR, Willems van Dijk K, Fronczek R, Wagner M, Scherer M, Göbel H, Sleegers K, Sveinsson OA, Pani L, Zoli M, Ramos-Quiroga JA, Dardiotis E, Steinberg A, Riedel-Heller S, Sjöstrand C, Thorgeirsson TE, Stefansson H, Southgate L, Trembath RC, Vandrovcova J, Noordam R, Paemeleire K, Stefansson K, Fann CS, Waldenlind E, Tronvik E, Jensen RH, Chen SP, Houlden H, Terwindt GM, Kubisch C, Maestrini E, Vikelis M, Pozo-Rosich P, Belin AC, Matharu M, van den Maagdenberg AMJM, Hansen TF, Ramirez A, and Zwart JA
- Subjects
- Male, Humans, Female, Risk Factors, Genome-Wide Association Study, Smoking adverse effects, Smoking genetics, Polymorphism, Single Nucleotide genetics, Genetic Predisposition to Disease genetics, Cluster Headache epidemiology, Cluster Headache genetics, Migraine Disorders
- Abstract
Objective: The objective of this study was to aggregate data for the first genomewide association study meta-analysis of cluster headache, to identify genetic risk variants, and gain biological insights., Methods: A total of 4,777 cases (3,348 men and 1,429 women) with clinically diagnosed cluster headache were recruited from 10 European and 1 East Asian cohorts. We first performed an inverse-variance genomewide association meta-analysis of 4,043 cases and 21,729 controls of European ancestry. In a secondary trans-ancestry meta-analysis, we included 734 cases and 9,846 controls of East Asian ancestry. Candidate causal genes were prioritized by 5 complementary methods: expression quantitative trait loci, transcriptome-wide association, fine-mapping of causal gene sets, genetically driven DNA methylation, and effects on protein structure. Gene set and tissue enrichment analyses, genetic correlation, genetic risk score analysis, and Mendelian randomization were part of the downstream analyses., Results: The estimated single nucleotide polymorphism (SNP)-based heritability of cluster headache was 14.5%. We identified 9 independent signals in 7 genomewide significant loci in the primary meta-analysis, and one additional locus in the trans-ethnic meta-analysis. Five of the loci were previously known. The 20 genes prioritized as potentially causal for cluster headache showed enrichment to artery and brain tissue. Cluster headache was genetically correlated with cigarette smoking, risk-taking behavior, attention deficit hyperactivity disorder (ADHD), depression, and musculoskeletal pain. Mendelian randomization analysis indicated a causal effect of cigarette smoking intensity on cluster headache. Three of the identified loci were shared with migraine., Interpretation: This first genomewide association study meta-analysis gives clues to the biological basis of cluster headache and indicates that smoking is a causal risk factor. ANN NEUROL 2023;94:713-726., (© 2023 The Authors. Annals of Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.)
- Published
- 2023
- Full Text
- View/download PDF
12. Galcanezumab for the treatment of chronic migraine and medication overuse headache: Real-world clinical evidence in a severely impaired patient population.
- Author
-
Guerzoni S, Baraldi C, Castro FL, Cainazzo MM, and Pani L
- Subjects
- Humans, Treatment Outcome, Double-Blind Method, Headache, Migraine Disorders drug therapy, Migraine Disorders prevention & control, Headache Disorders, Secondary drug therapy
- Abstract
Background: Galcanezumab is a monoclonal antibody acting against the calcitonin gene-related peptide approved for the preventive treatment of migraine. The aim of this article is to explore its effectiveness and safety of galcanezumab in chronic migraine (CM) with medication overuse-headache (MOH)., Methods: Seventy-eight patients were consecutively enrolled at the Modena headache center and followed up for 15 months. Visits were scheduled every 3 months, and the following variables were collected: the number of migraine days per month (MDM); the painkillers taken per month (PM); the number of days per month in which the patient took, at least, one painkiller; the six-item headache impact test; and the migraine disability assessment questionnaire (MIDAS) score. Demographic features of the analyzed sample were collected at the baseline and adverse events (AEs) were collected at every visit., Results: After 12 months, galcanezumab significantly reduced the MDM, the PM, the number of days on medication, the HIT-6 as well as the MIDAS scores (all p < .0001). The greatest amelioration was obtained in the first trimester of treatment. A higher MDM, a higher NRS score at the baseline, and a higher number of failed preventive treatments negatively predict the CM relief at the year of treatment. No serious AEs were registered and only one drop-out was due to AE., Conclusions: Galcanezumab is effective and safe for the treatment of patients affected by CM and MOH. Patients with a higher impairment at the baseline may found less benefits with galcanezumab., (© 2022 The Authors. Brain and Behavior published by Wiley Periodicals LLC.)
- Published
- 2023
- Full Text
- View/download PDF
13. Monoclonal anti-CGRP antibodies in post-menopausal women: a real-life study.
- Author
-
Guerzoni S, Baraldi C, Brovia D, Cainazzo MM, Castro FL, and Pani L
- Subjects
- Humans, Female, Postmenopause, Antibodies, Monoclonal therapeutic use, Calcitonin Gene-Related Peptide, Migraine Disorders drug therapy, Migraine Disorders chemically induced
- Abstract
Introduction: Migraine usually ameliorates after menopause. However, 10-29% of women still experience migraine attacks after menopause, especially if menopause is surgical. The use of monoclonal antibodies against the calcitonin gene-related peptide (CGRP) is changing the landscape of migraine treatment. This study aims to explore the effectiveness and safety of anti-CGRP monoclonal antibodies in women in menopause., Methods: Women affected by either migraine or chronic migraine and treated with an anti-CGRP monoclonal antibody for up to 1 year. Visits were scheduled every 3 months., Results: Women in menopause displayed a similar response compared to women of childbearing age. Among women in menopause, the women experiencing surgical menopause seemed to exhibit a similar response compared to the ones experiencing physiological menopause. Erenumab and galcanezumab displayed similar effectiveness in women in menopause. No serious adverse events were registered., Discussion: The effectiveness of anti-CGRP monoclonal antibodies is almost the same between women in menopause and women of childbearing age, without appreciable differences between the different antibodies., (© 2023. The Author(s) under exclusive licence to Belgian Neurological Society.)
- Published
- 2023
- Full Text
- View/download PDF
14. Self-administered subcutaneous diclofenac sodium in acute migraine attack: A randomized, double-blind, placebo-controlled dose-finding pilot study.
- Author
-
Geppetti P, De Cesaris F, Benemei S, Cortelli P, Cevoli S, Pierangeli G, Favoni V, Lisotto C, Usai S, Frediani F, Di Fiore P, D'Arrigo G, Tassorelli C, Sances G, Cainazzo MM, Baraldi C, Sarchielli P, Corbelli I, De Vanna G, Tedeschi G, and Russo A
- Subjects
- Double-Blind Method, Humans, Infusions, Intravenous, Pilot Projects, Diclofenac adverse effects, Migraine Disorders chemically induced, Migraine Disorders drug therapy
- Abstract
Background: A novel formulation of diclofenac, complexed with hydroxypropyl-β-cyclodextrin (HPβCD) as a solubility enhancer, in a prefilled syringe for self-administered subcutaneous injection may overcome the limitations of acute migraine treatments administered by oral, rectal, intramuscular, or intravenous routes., Methods: This multicentre, phase 2, double-blind, randomized, placebo-controlled, dose-finding pilot study evaluated the efficacy, safety and tolerability of three different doses (25/50/75 mg/1 mL) of subcutaneous diclofenac sodium in the treatment of an acute migraine attack in 122 subjects. The primary efficacy endpoint was the percentage of patients pain-free at 2 hours after the study drug injection., Results: A significantly higher percentage of patients in the 50 mg diclofenac group 14 (46.7%) were pain-free at 2 hours when compared with placebo: 9 (29.0%) ( p = 0.01). The 50 mg dose proved superior to placebo also in the majority of the secondary endpoints. The overall global impression favoured diclofenac vs placebo. There were no adverse events leading to study withdrawal. The majority of treatment-emergent adverse events were mild., Conclusions: The 50 mg dose of this novel formulation of diclofenac represents a valuable self-administered option for the acute treatment of migraine attacks. Trial registration: EudraCT Registration No. 2017-004828-29.
- Published
- 2022
- Full Text
- View/download PDF
15. Detoxification vs non-detoxification before starting an anti-CGRP monoclonal antibody in medication overuse headache.
- Author
-
Pensato U, Baraldi C, Favoni V, Mascarella D, Matteo E, Andrini G, Cainazzo MM, Cortelli P, Pierangeli G, Guerzoni S, and Cevoli S
- Subjects
- Antibodies, Monoclonal adverse effects, Calcitonin Gene-Related Peptide Receptor Antagonists therapeutic use, Headache chemically induced, Humans, Prospective Studies, Headache Disorders, Secondary chemically induced, Headache Disorders, Secondary drug therapy, Migraine Disorders chemically induced, Migraine Disorders drug therapy
- Abstract
Background: Medication overuse headache significantly contributes to the chronification process and treatment refractoriness of migraine. Currently, abrupt discontinuation of the overused medication still represents the best management strategy for these patients, challenging public health system resources., Methods: In this prospective study, chronic migraine and medication overuse headache sufferers with at least 28 days of analgesic consumption per month were included. Assessment of efficacy outcomes at three months were compared among patients who underwent in-hospital abrupt discontinuation of overused acute medication (YES-DETOX group) and patients who did not (NO-DETOX group) before starting an anti-CGRP monoclonal antibody., Results: Of 401 patients who received either erenumab or galcanezumab, 28% (n = 111) satisfied inclusion criteria (YES-DETOX n = 28; NO-DETOX n = 83). After three months of treatment, 59% (n = 65; 47/83 YES-DETOX; 18/28 NO-DETOX) patients reverted from medication overuse headache and 51% (n = 57; 42/83 YES-DETOX; 15/28 NO-DEOTX) achieved ≥50% reduction in monthly headache days; yet no statistical differences were observed between the two groups (p = 0.4788 and p = 0.8393, respectively). Monthly consumption of pain medication was the only baseline prognostic factor in multivariate analysis in the overall cohort (p = 0.016)., Conclusion: Our results support the emerging evidence that anti-CGRP monoclonal antibodies may be effective in medication overuse headache patients irrespective of detoxification, yet further studies are needed to draw definitive conclusions.
- Published
- 2022
- Full Text
- View/download PDF
16. Chronic migraine evolution after 3 months from erenumab suspension: real-world-evidence-life data.
- Author
-
Guerzoni S, Baraldi C, Pensato U, Favoni V, Lo Castro F, Cainazzo MM, Cevoli S, and Pani L
- Subjects
- Antibodies, Monoclonal, Humanized adverse effects, Calcitonin Gene-Related Peptide Receptor Antagonists adverse effects, Headache drug therapy, Humans, Headache Disorders, Secondary drug therapy, Migraine Disorders drug therapy
- Abstract
Background: Erenumab is a monoclonal antibody acting against calcitonin gene-related peptide receptor which has been found effective even for the treatment of chronic migraine (CM) complicated with medication overuse headache (MOH). According to the present guidelines, the treatment with erenumab should continue for up to 1 year. The aim of the present study is to explore the evolution of patients affected by CM and MOH at the baseline, after erenumab discontinuation., Methods: One hundred and eighty-five patients affected by CM and MOH were recruited and followed up after erenumab discontinuation. The number of migraine days per month, the number of painkillers taken per month, the number of days in which one medication was used for a month were collected every 30 days for the 3 months following erenumab suspension., Results: At the 3rd month after suspension, patients displayed a significantly higher number of migraine days per month, a significantly higher painkiller consumption, and a significantly higher migraine-related disability. A high body mass index and the presence of aura were positively correlated with the relapse of CM and MOH., Conclusion: Patients affected by CM and MOH at the baseline displayed a significant worsening of their headaches after erenumab discontinuation., (© 2022. Fondazione Società Italiana di Neurologia.)
- Published
- 2022
- Full Text
- View/download PDF
17. Oral Cannabinoid Preparations for the Treatment of Chronic Migraine: A Retrospective Study.
- Author
-
Baraldi C, Lo Castro F, Negro A, Ferrari A, Cainazzo MM, Pani L, and Guerzoni S
- Subjects
- Cohort Studies, Headache, Humans, Retrospective Studies, Treatment Outcome, Cannabinoids therapeutic use, Migraine Disorders drug therapy, Migraine Disorders prevention & control
- Abstract
Objective: To explore the effectiveness and safety of three oral cannabinoid preparations (FM2®, Istituto farmaceutico militare, Firenze, Italy; Bedrocan®, Bedrocan International, Vandaam, Netherlands; and Bediol®, Bedrocan International, Vandaam, Netherlands) in the treatment of chronic migraine., Design: Retrospective, cohort study., Subjects: Patients with chronic migraine who received FM2, Bedrocan, or Bediol daily for the off-label treatment of their headache, for up to 6 months., Methods: The number of migraine days per month, pain intensity, the number of acute medications taken per month, the number of days per month on which the patient took at least one acute medication, and adverse events were recorded at baseline and at 3 months and 6 months after the start of treatment with oral cannabinoid preparations., Results: The number of migraine days did not change significantly after the third month or the sixth month when compared with baseline (P = 0.1182). The pain intensity (P = 0.0004), the acute medication consumption (P = 0.0006), and the number of days per month in which patients took at least one acute medication significantly decreased when compared with baseline (P = 0.0004). No significant differences were found between patients who were still taking a preventive treatment for chronic migraine and those who were not (all P > 0.05). Different oral cannabinoid preparations displayed similar levels of effectiveness (all P > 0.05). The adverse events were mostly mild and occurred in 43.75% of patients., Conclusions: Oral cannabinoid preparations may have a role in reducing pain intensity and acute medication intake in patients with chronic migraine, but the magnitude of the effect seems modest; further studies are needed., (© The Author(s) 2021. Published by Oxford University Press on behalf of the American Academy of Pain Medicine. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2022
- Full Text
- View/download PDF
18. Real-life assessment of erenumab in refractory chronic migraine with medication overuse headache.
- Author
-
Pensato U, Baraldi C, Favoni V, Cainazzo MM, Torelli P, Querzani P, Pascazio A, Mascarella D, Matteo E, Quintana S, Asioli GM, Cortelli P, Pierangeli G, Guerzoni S, and Cevoli S
- Subjects
- Antibodies, Monoclonal, Humanized, Calcitonin Gene-Related Peptide Receptor Antagonists, Headache, Humans, Prospective Studies, Headache Disorders, Secondary drug therapy, Migraine Disorders drug therapy
- Abstract
Objective: To determine whether erenumab is effective and safe in refractory chronic migraine with medication overuse headache., Methods: In this prospective, multicentric, real-life study, chronic migraine with medication overuse headache patients who received erenumab were recruited. Study inclusion was limited to patients who previously failed onabotulinumtoxinA in addition to at least three other pharmacological commonly used migraine preventive medication classes., Results: Of 396 patients who received erenumab, 38% (n = 149) met inclusion criteria. After 3 months, 51% (n = 76) and 20% (n = 30) patients achieved ≥ 50% and ≥ 75% reduction in monthly headache days, respectively. Monthly pain medications intake decreased from 46.1 ± 35.3 to 16.8 ± 13.9 (p < 0.001), while monthly headache days decreased from 25.4 ± 5.4 to 14.1 ± 8.6 (p < 0.001). Increasing efficacy of erenumab over the study period was observed. Allodynia was a negative predictive factor of erenumab response (odds ratio = 0.47; p = 0.03). Clinical conversion to episodic migraine with no medication overuse was observed in 64% (n = 96) patients. No serious adverse events were observed., Conclusions: Erenumab reduced significantly migraine frequency and pain medication intake in refractory chronic migraine with MOH patients., (© 2021. Fondazione Società Italiana di Neurologia.)
- Published
- 2022
- Full Text
- View/download PDF
19. Erenumab for the preventive treatment of chronic migraine complicated with medication overuse headache: an observational, retrospective, 12-month real-life study.
- Author
-
Cainazzo MM, Baraldi C, Ferrari A, Lo Castro F, Pani L, and Guerzoni S
- Subjects
- Antibodies, Monoclonal, Humanized, Calcitonin Gene-Related Peptide Receptor Antagonists, Headache, Humans, Retrospective Studies, Headache Disorders, Secondary drug therapy, Migraine Disorders
- Abstract
Background: Erenumab is a monoclonal antibody blocking the calcitonin gene-related peptide receptor, which has been approved for the preventive treatment of chronic migraine (CM). The aim of this study was to explore the safety and effectiveness of erenumab in patients suffering from CM and medication overuse headache (MOH) in a real-life setting, up to 1 year., Methods: Data regarding 81 patients treated with erenumab were retrospectively analyzed. Every 3 months, the following variables were collected: the mean number of headache days per month (headache index (HI)), the average number of painkillers taken per month (analgesic consumption (AC)), the mean number of days with painkiller consumption (number of days on medication (NDM)), the headache intensity (numeric rating scale (NRS) score), the 6-item Headache Impact Test (HIT-6), and the Self-Reported Instrument to Assess Work-Related Difficulties in Patients With Migraine (HEADWORK) scores., Results: The HI, AC, and NDM and the NRS, HIT-6, and HEADWORK scores were significantly lower at every time point from the 3rd month onward compared to baseline (all P < 0.0001). No significant differences were found between patients who underwent painkiller detoxification before starting erenumab and those who did not (all P > 0.05). No significant differences were found between patients taking erenumab in combination with other preventive treatments and the ones taking it alone (all P ≥ 0.05). Five patients dropped out because of adverse events, which resolved after stopping erenumab., Conclusion: Erenumab was safe and effective for CM complicated with MOH. Painkiller withdrawal and the association with other preventive treatment(s) seem useless., (© 2021. Fondazione Società Italiana di Neurologia.)
- Published
- 2021
- Full Text
- View/download PDF
20. Predictors of response to erenumab after 12 months of treatment.
- Author
-
Baraldi C, Castro FL, Cainazzo MM, Pani L, and Guerzoni S
- Subjects
- Antibodies, Monoclonal, Humanized, Humans, Retrospective Studies, Calcitonin Gene-Related Peptide Receptor Antagonists, Migraine Disorders drug therapy, Migraine Disorders prevention & control
- Abstract
Objective: Erenumab is a monoclonal antibody acting against calcitonin gene-related peptide receptor and approved for the preventive treatment of chronic migraine. The aim of the present study is to identify clinical predictors of good response in patients with chronic migraine and medication overuse-headache., Material and Methods: This was a retrospective single-center not funded study. Enrolled patients were affected by chronic migraine and medication overuse-headache treated with erenumab monthly, up to 1 year. At 1 year, patients were classified as good responders if they displayed a ≥50% reduction in the number of headache days per months compared to the baseline., Results: After 1 year, a significant improvement in the number of headache days per months, analgesic consumption, 6-items headache impact test, and migraine disability assessment questionnaire scores were obtained compared to the baseline. Patients who obtained a ≥50% reduction in the number of headache days per month compared to the baseline displayed a longer history of medication overuse-headache, a higher number of painkillers taken per month at the baseline and a higher number of failed preventive treatments in the past., Conclusions: Patients with longer medication overuse-headache duration, higher analgesic intake, and a higher number of previous preventive treatment failures may receive less benefit with erenumab., (© 2021 The Authors. Brain and Behavior published by Wiley Periodicals LLC.)
- Published
- 2021
- Full Text
- View/download PDF
21. Identification of candidate proteomic markers in the serum of medication overuse headache patients: An exploratory study.
- Author
-
Pellesi L, Guerzoni S, Baraldi C, Cainazzo MM, Pini LA, and Bellei E
- Subjects
- Adult, Aged, Chromatography, Liquid methods, Electrophoresis, Gel, Two-Dimensional methods, Female, Humans, Male, Middle Aged, Proteomics methods, Tandem Mass Spectrometry methods, Biomarkers blood, Headache Disorders, Secondary blood
- Abstract
Purpose of the Study: The pathophysiological mechanism of medication overuse headache is uncertain; no distinctive markers have been described right now. The aim of this study was to conduct proteomic analyses on serum samples from patients with medication overuse headache and healthy individuals. Specifically, mono- (SDS-PAGE) and two-dimensional gel electrophoresis (2-DE) followed by liquid chromatography tandem mass spectrometry (LC-MS/MS) were used to evaluate changes in serum proteins., Main Findings: By SDS-PAGE, four over-expressed bands were revealed in patients, compared to controls. 2-DE combined with LC-MS/MS analysis allowed confirmation of some proteins preliminarily detected by SDS-PAGE: Hemopexin, alpha-1-acid glycoprotein 1, apolipoprotein A4 and haptoglobin. Moreover, other differential proteins were isolated, mostly increased in MOH patients: Alpha-1-antitrypsin, immunoglobulin heavy constant alpha 1, retinol binding protein and transthyretin. Only one protein, immunoglobulin kappa constant, was decreased in the patients' group., Conclusions: The investigation of the serum proteome can offer a better understanding about biological mechanisms underlying medication overuse headache. Specifically, medication overuse headache shares some serum biochemical markers with chronic pain conditions. Further studies might uncover the relevance of these proteins in medication overuse headache.
- Published
- 2020
- Full Text
- View/download PDF
22. Migraine Awareness in Italy and the Myth of "Cervical Arthrosis".
- Author
-
Rota E, Zucco R, Guerzoni S, Cainazzo MM, Pini LA, Catarci T, and Granella F
- Subjects
- Adolescent, Adult, Aged, Cervical Vertebrae diagnostic imaging, Cervical Vertebrae pathology, Cross-Sectional Studies, Female, Humans, Italy, Male, Middle Aged, Migraine Disorders drug therapy, Tension-Type Headache diagnosis, Young Adult, Diagnostic Errors, Health Knowledge, Attitudes, Practice, Migraine Disorders diagnosis, Neck Pain diagnosis, Osteoarthritis diagnosis
- Abstract
Objective: The primary aim of this study was to assess the degree of awareness migraine patients had of their condition. The secondary aims were to evaluate the frequency of an incorrect diagnosis of "cervical arthrosis" in patients unaware of having migraine and to compare the clinical features, diagnostic investigation, and treatment strategies between the 2 subgroups of migraineurs, that is, those with and without the incorrect diagnosis of "cervical arthrosis.", Methods: Patients, between 18 and 65 years, were consecutively referred to 5 Headache Centers in 2 Italian regions for a first visit. They fulfilled the diagnostic criteria for migraine (with/without aura, episodic/chronic) and were enrolled in this cross-sectional study. Each patient underwent a specific cranial/cervical musculoskeletal clinical examination., Results: A total of 117/250 subjects (46.8%) were unaware that they suffered from migraine. In these unaware subjects, the most frequently reported diagnosis was "cervical arthrosis" in 34/117 (29.1%), followed by tension-type headache in 23/117 (19%). The cervical region was the most common site of pain onset in the so-called "cervical arthrosis" group (52.9%, P < .0001), where also more pericranial (58.8%; P = .041) and neck (70.6%; P = .009) muscle tenderness, restricted range of cervical vertical (47.1%; P < .001), and lateral (29.4%; P = .040) movements were reported. More "cervical arthrosis patients" had been referred to an Emergency Department (88.2%; P = .011) and had undergone more cervical spine radiography (23.5%; P = .003) and magnetic resonance imaging (20.6%; P = .044). While they had used fewer triptans (11.8%; P = .007) and received less pharmacological prophylaxis (2.9%; P = .004)., Conclusions: In our sample, there were high misdiagnosis rates for migraine sufferers in Italy. The most common misdiagnosis, that is, "cervical arthrosis," led to misuse of healthcare facilities and had a negative impact on the migraine treatment., (© 2019 American Headache Society.)
- Published
- 2020
- Full Text
- View/download PDF
23. Easy tools to screen Italian women suffering from migraine with and without aura in early reproductive age.
- Author
-
Grandi G, Imbrogno MG, Cainazzo MM, Pini LA, Baraldi C, Guerzoni S, Nappi RE, and Facchinetti F
- Subjects
- Adolescent, Adult, Female, Humans, Italy, Mass Screening, Neurologic Examination, Surveys and Questionnaires, Young Adult, Migraine Disorders diagnosis
- Abstract
Objective: Early diagnosis of migraine with (MA)/without aura (MO) is vitally important to prevent adverse events during combined hormonal contraceptive (CHC) use and to provide personalized surveillance programs during pregnancy. The aim of this study is to provide clinicians with simple and fast tools to diagnose MO and MA in daily clinical practice., Study Design: This study was based on a questionnaire to women of early reproductive age (18-35 years old) then randomized to undergo a neurological consultation. The ID-migraine questionnaire (PIN) and visual aura rating scale (VARS) were used., Results: A total of 240 subjects were included in the study, with a total prevalence of MO diagnosed by PIN of 67.0% of subjects with headache, 49.2% of the total study population, and of MA by VARS of 12.5% subjects with headache, 9.2% of the total study population. Eighty-seven neurological examinations were randomly performed: PIN showed a sensitivity of 85.7% (95% CI 75.3%-92.9%) and a specificity of 52.9% (95% CI 27.8%-77.0%), while VARS displayed a sensitivity of 100.0% (95% CI 69.2%-100.0%) and a specificity of 45.5% (95% CI 16.8%-76.6%)., Conclusion: High sensitivity, in particular for the presence of MA, associated with low specificity suggest that PIN and VARS questionnaires can be effective tools to identify those young patients who require specific neurological examinations in view of the prescription of a CHC or pregnancy planning., (Copyright © 2019 Elsevier B.V. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
24. Exploration of candidate serum biomarkers potentially related to the chronic pain condition in Medication-overuse headache.
- Author
-
Pellesi L, Bellei E, Guerzoni S, Cainazzo MM, Baraldi C, Monari E, and Pini LA
- Subjects
- Adult, Animals, Chronic Pain blood, Female, Headache Disorders blood, Humans, Male, Middle Aged, Proteomics, Rats, Biomarkers blood, Headache Disorders, Secondary blood
- Abstract
Background: Medication Overuse Headache (MOH) is a prevalent and disabling disorder resulting from the overuse of analgesic drugs, triptans or other acute headache medications. In previous proteomic studies, several proteins have been found at high concentrations in the urine of MOH patients and in the serum of rats with neuropathic pain. The aim of this study was to compare the serum levels of lipocalin-type Prostaglandin D2 synthase (L-PGDS), Vitamin D-binding protein (VDBP), apolipoprotein E (APOE) and apolipoprotein A1 (APOA1) in MOH patients and healthy individuals, further exploring their relationship with cutaneous pain thresholds (CPTs) in the territories innervated by the trigeminal nerve., Methods: Sixty-nine MOH patients and 42 age- and sex-matched healthy volunteers were enrolled in the study. Von Frey-like filaments were applied to the skin territories innervated by the trigeminal nerve, to determine the CPTs. L-PGDS, VDBP, APOE and APOA1 were quantified in the serum by Enzyme-linked Immunosorbent Assay (ELISA). Clinical and laboratory data were collected. Comparisons between MOH patients and healthy individuals were performed using independent t test or χ
2 test. To correlate serum proteins with CPTs, Pearson correlation coefficient or Spearman's rank correlation coefficient were used., Results: CPTs were lower among MOH patients. L-PGDS, VDBP and APOE had significantly different serum concentrations between groups (p < 0.01), but no correlation was found with CPTs. APOA1 serum concentrations did not differ between patients and healthy individuals., Conclusions: L-PGDS, VDBP and APOE had abnormal serum levels in MOH patients, confirming their alteration in some conditions of chronic headache and neuropathic pain. However, they had no relationship with CPTs. The in-depth study of serum proteins represents a promising approach for a better understanding of MOH, as well as the detection of candidate biomarkers for chronic headache or the risks associated with overuse medications.- Published
- 2019
- Full Text
- View/download PDF
25. Genetic variation in CHRNA7 and CHRFAM7A is associated with nicotine dependence and response to varenicline treatment.
- Author
-
Cameli C, Bacchelli E, De Paola M, Giucastro G, Cifiello S, Collo G, Cainazzo MM, Pini LA, Maestrini E, and Zoli M
- Subjects
- Adolescent, Adult, Aged, Drug Resistance genetics, Female, Humans, Male, Middle Aged, Promoter Regions, Genetic, Tobacco Use Disorder drug therapy, DNA Copy Number Variations, Polymorphism, Single Nucleotide, Smoking Cessation Agents therapeutic use, Tobacco Use Disorder genetics, Varenicline therapeutic use, alpha7 Nicotinic Acetylcholine Receptor genetics
- Abstract
The role of nicotinic acetylcholine receptors (nAChR) in nicotine dependence (ND) is well established; CHRNA7, encoding the α7 subunit, has a still uncertain role in ND, although it is implicated in a wide range of neuropsychiatric conditions. CHRFAM7A, a hybrid gene containing a partial duplication of CHRNA7, is possibly involved in modulating α7 nAChR function. The aim of this study was to investigate the role of CHRNA7 and CHRFAM7A genetic variants in ND and to test the hypothesis that α7 nAChR variation may modulate the efficacy of varenicline treatment in smoking cessation. We assessed CHRNA7 and CHRFAM7A copy number, CHRFAM7A exon 6 ∆2 bp polymorphism, and sequence variants in the CHRNA7 proximal promoter in an Italian sample of 408 treatment-seeking smokers. We conducted case-control and quantitative association analyses using two smoking measures (cigarettes per day, CPD, and Fagerström Test for Nicotine Dependence, FTND). Next, driven by the hypothesis that varenicline may exert some of its therapeutic effects through activation of α7 nAChRs, we restricted the analysis to a subgroup of 142 smokers who received varenicline treatment. The CHRNA7 promoter variant rs28531779 showed association with both smoking quantitative measures (FNTD p = 0.026, β = 0.89, 95% CI 0.11-1.67; CPD p = 0.006, β = 4.82 95% CI 1.42-8.22). Moreover, in the varenicline-treated subgroup we observed association of CHRFAM7A copy number with 6 months smoking abstinence (p = 0.035, OR = 3.18, 95% CI = 1.09-9.30). Thus, our study points to a possible role of genetic variation in CHRNA7 and CHRFAM7A in tobacco addiction mechanisms and response to varenicline treatment.
- Published
- 2018
- Full Text
- View/download PDF
26. Pharmacokinetics and tolerability of oral cannabis preparations in patients with medication overuse headache (MOH)-a pilot study.
- Author
-
Pellesi L, Licata M, Verri P, Vandelli D, Palazzoli F, Marchesi F, Cainazzo MM, Pini LA, and Guerzoni S
- Subjects
- Administration, Oral, Adult, Area Under Curve, Biological Availability, Cannabinoids administration & dosage, Cannabinoids pharmacokinetics, Chromatography, Liquid methods, Cross-Over Studies, Female, Humans, Italy, Male, Middle Aged, Pilot Projects, Plant Extracts adverse effects, Plant Extracts pharmacokinetics, Tandem Mass Spectrometry methods, Cannabinoids isolation & purification, Cannabis chemistry, Headache Disorders, Secondary drug therapy, Plant Extracts administration & dosage
- Abstract
Purpose: The recent release of a medical cannabis strain has given a new impulse for the study of cannabis in Italy. The National Health Service advises to consume medical cannabis by vaporizing, in decoction or oil form. This is the first study that explores the pharmacokinetics and tolerability of a single oral dose of cannabis as decoction (200 ml) or in olive oil (1 ml), as a first step to improve the prescriptive recommendations., Methods: This is a single-center, open-label, two-period crossover study designed to assess the pharmacokinetics and tolerability of oral cannabis administered to 13 patients with medication overuse headache (MOH). A liquid chromatography tandem-mass spectrometry (LC-MS/MS) method was conducted for the quantification of THC, CBD, 11-OH-THC, THC-COOH, THC-COOH-glucuronide, THCA-A, and CBDA. Blood pressure, heart rate, and a short list of symptoms by numerical rating scale (NRS) were assessed., Results: Decoctions of cannabis showed high variability in cannabinoids content, compared to cannabis oil. For both preparations, THCA-A and CBDA were the most widely absorbed cannabinoids, while THC and CBD were less absorbed. The most important differences concern the bioavailability of THC, higher in oil (AUC
0-24 7.44, 95% CI 5.19, 9.68) than in decoction (AUC0-24 3.34, 95% CI 2.07, 4.60), and the bioavailability of CBDA. No serious adverse events were reported., Conclusions: Cannabis decoction and cannabis oil showed different pharmacokinetic properties, as well as distinct consequences on patients. This study was performed in a limited number of patients; future studies should be performed to investigate the clinical efficacy in larger populations.- Published
- 2018
- Full Text
- View/download PDF
27. Therapeutical approaches to paroxysmal hemicrania, hemicrania continua and short lasting unilateral neuralgiform headache attacks: a critical appraisal.
- Author
-
Baraldi C, Pellesi L, Guerzoni S, Cainazzo MM, and Pini LA
- Subjects
- Amines administration & dosage, Cyclohexanecarboxylic Acids administration & dosage, Female, Fructose administration & dosage, Fructose analogs & derivatives, Gabapentin, Humans, Indomethacin administration & dosage, Lamotrigine, Lidocaine administration & dosage, Male, Neuralgia diagnosis, Neuralgia drug therapy, Neuralgia epidemiology, Paroxysmal Hemicrania diagnosis, Reproducibility of Results, SUNCT Syndrome diagnosis, Surveys and Questionnaires, Topiramate, Triazines administration & dosage, Trigeminal Autonomic Cephalalgias diagnosis, Trigeminal Autonomic Cephalalgias drug therapy, Trigeminal Autonomic Cephalalgias epidemiology, gamma-Aminobutyric Acid administration & dosage, Analgesics administration & dosage, Anticonvulsants administration & dosage, Paroxysmal Hemicrania drug therapy, Paroxysmal Hemicrania epidemiology, SUNCT Syndrome drug therapy, SUNCT Syndrome epidemiology
- Abstract
Background: Hemicrania continua (HC), paroxysmal hemicrania (PH) and short lasting neuralgiform headache attacks (SUNCT and SUNA) are rare syndromes with a difficult therapeutic approach. The aim of this review is to summarize all articles dealing with treatments for HC, PH, SUNCT and SUNA, comparing them in terms of effectiveness and safety., Methods: A survey was performed using the pubmed database for documents published from the 1st January 1989 onwards. All types of articles were considered, those ones dealing with symptomatic cases and non-English written ones were excluded., Results: Indomethacin is the best treatment both for HC and PH. For the acute treatment of HC, piroxicam and celecoxib have shown good results, whilst for the prolonged treatment celecoxib, topiramate and gabapentin are good options besides indomethacin. For PH the best drug besides indomethacin is piroxicam, both for acute and prolonged treatment. For SUNCT and SUNA the most effective treatments are intravenous or subcutaneous lidocaine for the acute treatment of active phases and lamotrigine for the their prevention. Other effective therapeutic options are intravenous steroids for acute treatment and topiramate for prolonged treatment. Non-pharmacological techniques have shown good results in SUNCT and SUNA but, since they have been tried on a small number of patients, the reliability of their efficacy is poor and their safety profile mostly unknown., Conclusions: Besides a great number of treatments tried, HC, PH, SUNCT and SUNA management remains difficult, according with their unknown pathogenesis and their rarity, which strongly limits the studies upon these conditions. Further studies are needed to better define the treatment of choice for these conditions.
- Published
- 2017
- Full Text
- View/download PDF
28. Long-term Treatment Benefits and Prolonged Efficacy of OnabotulinumtoxinA in Patients Affected by Chronic Migraine and Medication Overuse Headache over 3 Years of Therapy.
- Author
-
Guerzoni S, Pellesi L, Baraldi C, Cainazzo MM, Negro A, Martelletti P, and Pini LA
- Abstract
Background: Chronic migraine (CM) affects about the 2% of the general population and it has been recognized as one of the most-disabling conditions worldwide by the World Health Organization. CM is often associated with the overuse of abortive medication, which determines the worsening of headache itself and the development of a secondary headache called medication overuse headache. The management of these associated conditions is difficult, but a growing amount of evidence is pointing out the effectiveness and the good safety profile of OnabotulinumtoxinA (OnabotA). Despite this, data on OnabotA effects and safety in long-term use lack. The purpose of the present article is to retrospectively assess the efficacy and safety of OnabotA in a cohort of chronic migraineurs with drug overuse from the 18th month of treatment until the third year., Materials and Methods: 90 chronic migraineurs with medication overuse were enrolled between January 2013 and February 2017. All patients were treated with OnabotA according to PREEMPT dictates. Before every injection session the headache index, the analgesic consumption, the visual analog scale for pain score, the 36-items short form health survey questionnaire score, the 6-items headache impact test (HIT-6) score and the Zung self-rating anxiety and depression scale scores were collected. Adverse events were carefully registered. A simple linear regression was performed to explore the mean changes in the abovementioned parameters for a single injection session and mean comparison tests were performed using the one-way analysis of variance followed by Tukey-Kramer post-hoc test., Results: A significantly improvement for a single injection was registered for all the above-mentioned parameters. Headache index, analgesic consumption, visual analog pain scale, and 6-items HIT-6 scores were significantly lower than baseline from the 18th month of treatment onwards. The 36-items short form health survey questionnaire scores were significantly higher than baseline at every injections session from the 18th months onwards. Zung scales did not change. No serious adverse events were assessed and no adverse events-related drop-outs were seen., Conclusion: OnabotA effectiveness and safety last until 3 years of therapy, raising the possibility of the use of this therapy even for many years in CM prevention.
- Published
- 2017
- Full Text
- View/download PDF
29. A genome-wide analysis in cluster headache points to neprilysin and PACAP receptor gene variants.
- Author
-
Bacchelli E, Cainazzo MM, Cameli C, Guerzoni S, Martinelli A, Zoli M, Maestrini E, and Pini LA
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Cluster Headache diagnosis, Female, Genetic Predisposition to Disease genetics, Genetic Testing methods, Humans, Male, Middle Aged, Polymorphism, Single Nucleotide genetics, Young Adult, Cluster Headache genetics, Genetic Variation genetics, Genome-Wide Association Study methods, Neprilysin genetics, Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide genetics
- Abstract
Background: Cluster Headache (CH) is a severe primary headache, with a poorly understood pathophysiology. Complex genetic factors are likely to play a role in CH etiology; however, no confirmed gene associations have been identified. The aim of this study is to identify genetic variants influencing risk to CH and to explore the potential pathogenic mechanisms., Methods: We have performed a genome-wide association study (GWAS) in a clinically well-defined cohort of 99 Italian patients with CH and in a control sample of 360 age-matched sigarette smoking healthy individuals, using the Infinium PsychArray (Illumina), which combines common highly-informative genome-wide tag SNPs and exonic SNPs. Genotype data were used to carry out a genome-wide single marker case-control association analysis using common SNPs, and a gene-based association analysis focussing on rare protein altering variants in 745 candidate genes with a putative role in CH., Results: Although no single variant showed statistically significant association at the genome-wide threshold, we identified an interesting suggestive association (P = 9.1 × 10
-6 ) with a common variant of the PACAP receptor gene (ADCYAP1R1). Furthermore, gene-based analysis provided significant evidence of association (P = 2.5 × 10-5 ) for a rare potentially damaging missense variant in the MME gene, encoding for the membrane metallo-endopeptidase neprilysin., Conclusions: Our study represents the first genome-wide association study of common SNPs and rare exonic variants influencing risk for CH. The most interesting results implicate ADCYAP1R1 and MME gene variants in CH susceptibility and point to a role for genes involved in pain processing. These findings provide new insights into the pathogenesis of CH that need further investigation and replication in larger CH samples.- Published
- 2016
- Full Text
- View/download PDF
30. NDP-α-MSH attenuates heart and liver responses to myocardial reperfusion via the vagus nerve and JAK/ERK/STAT signaling.
- Author
-
Ottani A, Giuliani D, Neri L, Calevro A, Canalini F, Vandini E, Cainazzo MM, Ruberto IA, Barbieri A, Rossi R, and Guarini S
- Subjects
- Acetylcholine metabolism, Animals, Apoptosis drug effects, Blood Pressure drug effects, Cardiotonic Agents pharmacology, Heart drug effects, Heart physiopathology, Liver drug effects, Liver pathology, Liver physiopathology, Male, Myocardial Reperfusion Injury pathology, Myocardial Reperfusion Injury physiopathology, Myocardium pathology, Rats, Rats, Wistar, alpha-MSH pharmacology, Extracellular Signal-Regulated MAP Kinases metabolism, Janus Kinases metabolism, Myocardial Reperfusion Injury prevention & control, STAT3 Transcription Factor metabolism, Signal Transduction drug effects, Vagus Nerve drug effects, alpha-MSH analogs & derivatives
- Abstract
Melanocortin peptides afford cardioprotection during myocardial ischemia/reperfusion via janus kinases (JAK), extracellular signal-regulated kinases (ERK) and signal transducers/activators of transcription (STAT) pathways. Here we investigated whether melanocortin-induced modulation of the JAK/ERK/STAT signaling occurs via the cholinergic anti-inflammatory pathway, focusing our study on cardiac and hepatic responses to prolonged myocardial ischemia/reperfusion. Ischemia was produced in rats by ligature of the left anterior descending coronary artery for 30min; effects of ischemia/reperfusion were evaluated using Western blot of heart and liver proteins. Intravenous treatment, during coronary artery occlusion, with the melanocortin analog (Nle(4), D-Phe(7))α-melanocyte-stimulating hormone (NDP-α-MSH) induced a left ventricle up-regulation of the cardioprotective transcription factors pJAK2, pERK1/2 and pTyr-STAT3 (JAK-dependent), and a reduction in the levels of the inflammatory mediators tumor necrosis factor-α (TNF-α) and pJNK (a transcription factor also involved in apoptosis), as assessed at the end of the 2-h reperfusion period. Further, these beneficial effects of NDP-α-MSH were associated with heart over-expression of the pro-survival proteins heme oxygenase-1 (HO-1) and Bcl-XL, and decrease of ventricular arrhythmias and infarct size. In the liver NDP-α-MSH induced a decrease in the pJAK2 and pTyr-STAT3 levels, and strongly reduced pERK1/2 expression. In the liver of ischemic rats NDP-α-MSH also blunted pJNK activity and TNF-α expression, and up-regulated Bcl-XL. Bilateral cervical vagotomy prevented all effects of NDP-α-MSH, both in the heart and liver. These results indicate that melanocortins inhibit heart and liver damage triggered by prolonged myocardial ischemia/reperfusion likely, as main mechanism, via the vagus nerve-mediated modulation of the JAK/STAT/ERK signaling pathways., (Copyright © 2015 Elsevier B.V. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
31. Proteomic research of proteins involved in pain expression in an animal model of chronic pain.
- Author
-
Bellei E, Bergamini S, Monari E, Cuoghi A, Zoli M, Tomasi A, Cainazzo MM, Guerzoni S, and Pini LA
- Published
- 2015
- Full Text
- View/download PDF
32. O015. Evaluation of the genetic polymorphism of the α3 (CHRNA3) and α5 (CHRNA5) nicotinic receptor subunits, in patients with cluster headache.
- Author
-
Cainazzo MM, Tiraferri I, Ciccarese M, Martinelli A, Cameli C, Bacchelli E, Zoli M, and Pini LA
- Published
- 2015
- Full Text
- View/download PDF
33. P045. OnabotulinumtoxinA: long term treatment for chronic migraine with medication overuse.
- Author
-
Guerzoni S, Cainazzo MM, and Pini LA
- Published
- 2015
- Full Text
- View/download PDF
34. Impact of continuing or quitting smoking on episodic cluster headache: a pilot survey.
- Author
-
Ferrari A, Zappaterra M, Righi F, Ciccarese M, Tiraferri I, Pini LA, Guerzoni S, and Cainazzo MM
- Subjects
- Female, Humans, Male, Middle Aged, Pilot Projects, Surveys and Questionnaires, Cluster Headache etiology, Smoking adverse effects, Smoking Cessation
- Abstract
Background: The majority of patients suffering from cluster headache (CH) are smokers and it has been suggested that smoking may trigger the development of CH. The aim of this pilot survey was to describe: 1. the differences between current, former, and never smokers CH patients; 2. if smoking changed during an active cluster period; 3. if CH changed after quitting., Methods: All outpatients with episodic CH according to the criteria of ICHD-II who were consecutively seen for the first time from October 2010 to April 2012 at a headache centre were interviewed by phone using a specifically prepared questionnaire. Statistical differences between continuous variables were analysed by the Student's t-test or the one-way analysis of variance (ANOVA), followed by Newman-Keuls post-hoc testing. Comparisons between percentages were made using the Chi-square test or Fisher's exact test. All data were expressed as the mean ± standard deviation (SD)., Results: Among a total of 200 patients surveyed (172 males, 28 females; mean age ± SD: 48.41 ± 12 years) there were 60%, 21%, and 19% of current, former, and never smokers, respectively. Current smokers reported longer active periods (12.38 ± 10 weeks) and a higher maximum number of attacks per day (3.38 ± 1) compared to never smoker CH patients (5.68 ± 4 weeks, P <0.05 and 2.47 ± 1, P <0.05, respectively). During the active period most of the patients stated to decrease (45.7%) or not to change (45.7%) the number of cigarettes smoked. Among those who decreased smoking, most (83.8%) reported that they had less desire to smoke. After quitting, the majority of former smokers stated that their headache had not changed., Conclusions: Patients with episodic CH who are also smokers appear to have a more severe form of the disorder. However, it is unlikely that between CH and smoking there is a causal relationship, as CH patients rarely improve quitting smoking.
- Published
- 2013
- Full Text
- View/download PDF
35. Nabilone for the treatment of medication overuse headache: results of a preliminary double-blind, active-controlled, randomized trial.
- Author
-
Pini LA, Guerzoni S, Cainazzo MM, Ferrari A, Sarchielli P, Tiraferri I, Ciccarese M, and Zappaterra M
- Subjects
- Adult, Aged, Analgesics, Non-Narcotic therapeutic use, Cross-Over Studies, Double-Blind Method, Dronabinol therapeutic use, Drug Overdose complications, Female, Headache Disorders, Secondary complications, Humans, Ibuprofen therapeutic use, Male, Middle Aged, Pain Measurement, Quality of Life, Treatment Outcome, Anti-Anxiety Agents therapeutic use, Dronabinol analogs & derivatives, Drug Overdose drug therapy, Headache Disorders, Secondary drug therapy
- Abstract
Medication overuse headache (MOH) is a severe burden to sufferers and its treatment has few evidence-based indications. The aim of this study is to evaluate efficacy and safety of nabilone in reducing pain and frequency of headache, the number of analgesic intake and in increasing the quality of life on patients with long-standing intractable MOH. Thirty MOH patients were enrolled at the University of Modena's Interdepartmental Centre for Research on Headache and Drug Abuse (Italy) in a randomized, double-blind, active-controlled, crossover study comparing nabilone 0.5 mg/day and ibuprofen 400 mg. The patients received each treatment orally for 8 weeks (before nabilone and then ibuprofen or vice versa), with 1 week wash-out between them. Randomization and allocation (ratio 1:1) were carried out by an independent pharmacy through a central computer system. Participants, care givers, and those assessing the outcomes were blinded to treatment sequence. Twenty-six subjects completed the study. Improvements from baseline were observed with both treatments. However, nabilone was more effective than ibuprofen in reducing pain intensity and daily analgesic intake (p < 0.05); moreover, nabilone was the only drug able to reduce the level of medication dependence (-41 %, p < 0.01) and to improve the quality of life (p < 0.05). Side effects were uncommon, mild and disappeared when nabilone was discontinued. This is the first randomized controlled trial demonstrating the benefits of nabilone on headache, analgesic consumption and the quality of life in patients with intractable MOH. This drug also appears to be safe and well-tolerated. Larger scale studies are needed to confirm these preliminary findings.
- Published
- 2012
- Full Text
- View/download PDF
36. Basal cutaneous pain threshold in headache patients.
- Author
-
Zappaterra M, Guerzoni S, Cainazzo MM, Ferrari A, and Pini LA
- Subjects
- Acute Disease, Adult, Aged, Female, Headache epidemiology, Headache Disorders, Secondary epidemiology, Headache Disorders, Secondary physiopathology, Humans, Hyperalgesia epidemiology, Male, Middle Aged, Migraine Disorders epidemiology, Migraine Disorders physiopathology, Prevalence, Surveys and Questionnaires, Tension-Type Headache epidemiology, Tension-Type Headache physiopathology, Young Adult, Headache physiopathology, Hyperalgesia physiopathology, Pain Threshold physiology, Skin innervation
- Abstract
The aim of this study was to analyze cutaneous pain threshold (CPT) during the interictal phase in headache patients, and the relationships between headache frequency and analgesic use. A consecutive series of 98 headache patients and 26 sex- and age-balanced controls were evaluated. Acute allodynia (AA) was assessed by Jakubowski questionnaire, and interictal allodynia (IA) by a skin test with calibrated monofilaments. AA is widely known as a symptom more present in migraine than in TTH spectrum: in our study this was confirmed only in cases of episodic attacks. When headache index rises towards chronicization, the prevalence of AA increases in both headache spectrums (χ (2) 13.55; p < 0.01). AA was associated with IA only in cases of chronic headache. When headache becomes chronic, mostly in presence of medication overuse, interictal CPT decreases and IA prevalence increases (χ (2) 20.44; p < 0.01), with closer association than AA. In MOH patients there were no significant differences depending on the diagnosis of starting headache (migraine or tension type headache) and, in both groups, we found the overuse of analgesics plays an important role: intake of more than one daily drug dramatically reduces the CPT (p < 0.05). Thus, when acute allodynia increases frequency, worsens or appears for the first time in patients with a long-standing history of chronic headache, it could reasonably suggest that the reduction of CPT had started, without using a specific practical skin test but simply by questioning clinical headache history. In conclusion, these results indicate that the role of medication overuse is more important than chronicization in lowering CPT, and suggest that prolonged periods of medication overuse can interfere with pain perception by a reduction of the pain threshold that facilitates the onset of every new attack leading to chronicization.
- Published
- 2011
- Full Text
- View/download PDF
37. Both early and delayed treatment with melanocortin 4 receptor-stimulating melanocortins produces neuroprotection in cerebral ischemia.
- Author
-
Giuliani D, Mioni C, Altavilla D, Leone S, Bazzani C, Minutoli L, Bitto A, Cainazzo MM, Marini H, Zaffe D, Botticelli AR, Pizzala R, Savio M, Necchi D, Schiöth HB, Bertolini A, Squadrito F, and Guarini S
- Subjects
- Animals, Apoptosis, Blotting, Western, Brain metabolism, Brain pathology, Caspase 3, Caspases metabolism, Central Nervous System, Cytokines metabolism, Cytoplasm metabolism, DNA Damage, Disease Models, Animal, Enzyme Activation, Gerbillinae, Hippocampus metabolism, Hypoxia therapy, Inflammation, Ischemia metabolism, Learning, MAP Kinase Signaling System, Male, Maze Learning, Memory, Models, Statistical, Neurons metabolism, Receptor, Melanocortin, Type 4 metabolism, Stroke therapy, Time Factors, Treatment Outcome, alpha-MSH metabolism, bcl-2-Associated X Protein metabolism, bcl-X Protein metabolism, Brain Ischemia pathology, Brain Ischemia therapy, Neuroprotective Agents pharmacology, Receptor, Melanocortin, Type 4 therapeutic use
- Abstract
Ischemic stroke is one of the main causes of death and disability. We investigated whether melanocortin peptides, which have protective effects in severe hypoxic conditions, also produce neuroprotection in a gerbil model of ischemic stroke. A 10-min period of global cerebral ischemia, induced by occluding both common carotid arteries, caused impairment in spatial learning and memory that was associated with activation of inflammatory and apoptotic pathways, including severe DNA damage and delayed neuronal death, in the hippocampus. Treatment with nanomolar doses of the melanocortin analog [Nle4, D-Phe7] alpha-MSH [which activates the melanocortin receptor subtypes (MC) mainly expressed in central nervous system, namely MC3 and MC4] modulated the inflammatory and apoptotic cascades and reduced hippocampus injuries even when delayed up to 9 h after ischemia, with consequent dose-dependent improvement in subsequent functional recovery. The selective MC3 receptor agonist gamma2-MSH had no protective effects. Pharmacological blockade of MC4 receptors prevented the neuroprotective effects of [Nle4, D-Phe7] alpha-MSH and worsened some ischemia outcomes. Together, our findings suggest that MC4 receptor-stimulating melanocortins might provide potential to develop a class of drugs with a broad treatment window for a novel approach to neuroprotection in ischemic stroke.
- Published
- 2006
- Full Text
- View/download PDF
38. Risk-benefit and cost-benefit ratio in headache treatment.
- Author
-
Pini LA, Cainazzo MM, and Brovia D
- Subjects
- Cost-Benefit Analysis, Humans, Migraine Disorders prevention & control, Risk Assessment, Vasoconstrictor Agents administration & dosage, Vasoconstrictor Agents adverse effects, Drug Costs, Migraine Disorders drug therapy, Migraine Disorders economics, Vasoconstrictor Agents economics
- Abstract
The cost-benefit and the risk-benefit ratios are two of the most relevant items in ongoing health organisation procedures. The choice of a new or an old therapeutic treatment depends on a number of factors and the evaluation of the cost, in terms of economics, but also in terms of quality of life and type of facilities necessary for one treatment are crucial criteria. Therefore, we have to consider in evaluating treatment strategies not only the activity of a drug in reaching the main end-points, (i.e., pain free or headache relief) but also the safety and perception of safety by patients, and the cost effectiveness, including indirect costs compared with personal and social benefits. Because it is reasonable that a subgroup of migraine patients may have a clinically progressive disorder, studies should be necessary to assess strategies for migraine treatments.
- Published
- 2005
- Full Text
- View/download PDF
39. Pharmacokinetics of a new extended-release nifedipine formulation following a single oral dose, in human volunteers.
- Author
-
Cainazzo MM, Pinetti D, Savino G, Bartiromo M, Forgione A, and Bertolini A
- Subjects
- Administration, Oral, Adult, Area Under Curve, Blood Pressure drug effects, Delayed-Action Preparations, Female, Heart Rate drug effects, Humans, Male, Metabolic Clearance Rate, Middle Aged, Nifedipine administration & dosage, Nifedipine adverse effects, Nifedipine blood, Nifedipine pharmacokinetics
- Abstract
This study aimed to define the pharmacokinetics of nifedipine following oral administration of a new extended-release formulation. Twelve healthy volunteers of both sexes, aged 39 +/- 4 years, were treated with a single oral tablet of a new extended-release formulation containing 40 mg of nifedipine. Samples of venous blood were taken before dosing, after 30 min and at 1, 2, 4, 8, 12, 16, 20 and 24 h after administration. Nifedipine concentration was measured by means of a high-performance liquid chromatography method. Noncompartmental pharmacokinetics parameters were then calculated. The plasma concentration of nifedipine increased slowly and in seven subjects biphasic peaks occurred. The mean values were as follows: t(max): 8.5 +/- 1.2 h; C(max): 36.55 +/- 6.76 ng/ml; AUC: 347.06 +/- 51.61 ng/h/ml; AUC 409.99 +/- 61.08 ng/h/ml; A(half-life): 2.26 +/- 0.36 h; D(half-life): 2.43 +/- 0.44 h; E(half-life): 4.62 +/- 0.79 h. Twenty-four hours after administration nifedipine was still detectable (3.17 +/- 0.67 ng/ml). Arterial blood pressure decreased and heart rate increased concurrently and proportionally to the increase in nifedipine concentration. Extended-release nifedipine formulations have better tolerability profiles than immediate-release formulations, which are at present not recommended in the treatment of hypertension, hypertensive crises or myocardial infarction. This new extended-release formulation has interesting pharmacokinetic parameters and may be effective in conditions in which dihydropyridine calcium channel blockers are indicated.
- Published
- 2005
40. Adrenocorticotropin reverses hemorrhagic shock in anesthetized rats through the rapid activation of a vagal anti-inflammatory pathway.
- Author
-
Guarini S, Cainazzo MM, Giuliani D, Mioni C, Altavilla D, Marini H, Bigiani A, Ghiaroni V, Passaniti M, Leone S, Bazzani C, Caputi AP, Squadrito F, and Bertolini A
- Subjects
- Acute Disease, Animals, Atropine pharmacology, Chlorisondamine therapeutic use, Electrophoretic Mobility Shift Assay, Female, I-kappa B Proteins metabolism, Liver metabolism, Male, NF-kappa B metabolism, RNA, Messenger metabolism, Rats, Rats, Wistar, Receptors, Nicotinic drug effects, Reverse Transcriptase Polymerase Chain Reaction, Tumor Necrosis Factor-alpha analysis, Tumor Necrosis Factor-alpha genetics, Vagus Nerve drug effects, Cosyntropin therapeutic use, Shock, Hemorrhagic drug therapy, Shock, Hemorrhagic physiopathology, Vagus Nerve physiopathology
- Abstract
Objective: Several melanocortin peptides have a prompt and sustained resuscitating effect in conditions of hemorrhagic shock. The transcription nuclear factor kappaB (NF-kappaB) triggers a potentially lethal systemic inflammatory response, with marked production of tumor necrosis factor-alpha (TNF-alpha), in hemorrhagic shock. Here we investigated whether the hemorrhagic shock reversal produced by the melanocortin ACTH-(1-24) (adrenocorticotropin) depends on the activation of the recently recognized, vagus nerve-mediated, brain "cholinergic anti-inflammatory pathway"., Methods and Results: Anesthetized rats were stepwise bled until mean arterial pressure (MAP) stabilized at 20-25 mm Hg. The severe hypovolemia was incompatible with survival, and all saline-treated animals died within 30 min. In rats intravenously (i.v.) treated with ACTH-(1-24), neural efferent activity along vagus nerve (monitored by means of a standard system for extracellular recordings) was markedly increased, and the restoration of cardiovascular and respiratory functions was associated with blunted NF-kappaB activity and with decreased TNF-alpha mRNA liver content and TNF-alpha plasma levels. Bilateral cervical vagotomy, pretreatment with the melanocortin MC(4) receptor antagonist HS014, atropine sulfate or chlorisondamine, but not with atropine methylbromide, prevented the life-saving effect of ACTH-(1-24) and the associated effects on NF-kappaB activity and TNF-alpha levels. HS014 and atropine sulfate prevented, too, the ACTH-(1-24)-induced increase in neural efferent vagal activity, and accelerated the evolution of shock in saline-treated rats., Conclusions: The present data show, for the first time, that the melanocortin ACTH-(1-24) suppresses the NF-kappaB-dependent systemic inflammatory response triggered by hemorrhage, and reverses shock condition, by brain activation (in real-time) of the "cholinergic anti-inflammatory pathway", this pathway seeming to be melanocortin-dependent., (Copyright 2004 European Society of Cardiology)
- Published
- 2004
- Full Text
- View/download PDF
41. Further evidence that melanocortins prevent myocardial reperfusion injury by activating melanocortin MC3 receptors.
- Author
-
Mioni C, Giuliani D, Cainazzo MM, Leone S, Bazzani C, Grieco P, Novellino E, Tomasi A, Bertolini A, and Guarini S
- Subjects
- Animals, Coronary Disease complications, Coronary Disease physiopathology, Cosyntropin antagonists & inhibitors, Cosyntropin blood, FMRFamide chemistry, FMRFamide metabolism, Female, Hypotension complications, Hypotension drug therapy, Hypotension prevention & control, Injections, Intravenous, Lidocaine pharmacology, Male, Melanocyte-Stimulating Hormones physiology, Myocardial Reperfusion Injury complications, Myocardial Reperfusion Injury mortality, Rats, Rats, Wistar, Receptor, Melanocortin, Type 3 physiology, Signal Transduction, Tachycardia, Ventricular complications, Tachycardia, Ventricular prevention & control, Time Factors, Ventricular Fibrillation complications, Ventricular Fibrillation prevention & control, alpha-MSH physiology, gamma-MSH antagonists & inhibitors, gamma-MSH chemistry, gamma-MSH physiology, Cosyntropin pharmacology, Melanocyte-Stimulating Hormones pharmacology, Myocardial Reperfusion Injury prevention & control, Receptor, Melanocortin, Type 3 drug effects, alpha-MSH pharmacology, gamma-MSH pharmacology
- Abstract
In rats subjected to myocardial ischemia/reperfusion, melanocortin peptides, including gamma(1)-melanocyte-stimulating hormone (gamma(1)-MSH), are able to exert a protective effect by stimulating brain melanocortin MC(3) receptors. A non-melanocortin receptor belonging to a group of receptors for Phe-Met-Arg-Phe-NH(2) (FMRFamide)-like peptides may be involved in some of the cardiovascular effects of the gamma-MSHs. FMRFamide-like peptides and gamma(1)-/gamma(2)-MSH share, among other things, the C-terminal Arg-Phe sequence, which seems to be essential for cardiovascular effects in normal animals. So we aimed to further investigate which receptor and which structure are involved in the protective effects of melanocortins in anesthetized rats subjected to myocardial ischemia by ligature of the left anterior descending coronary artery (5 min), followed by reperfusion. In saline-treated rats, reperfusion induced, within a few seconds, a high incidence of ventricular tachycardia and ventricular fibrillation, and a high percentage of death within the 5 min of observation period. Reperfusion was associated with a massive increase in free radical blood levels and with an abrupt and marked fall in systemic arterial pressure. The i.v. treatment (162 nmol/kg) during the ischemic period with the adrenocorticotropin fragment 1-24 [ACTH-(1-24): the reference protective melanocortin which binds all melanocortin receptors], as well as with both the melanocortin MC(3) receptor agonists gamma(2)-MSH and [D-Trp(8)]gamma(2)-MSH, reduced the incidence of ventricular tachycardia, ventricular fibrillation and death, the increase in free radical blood levels and the fall in arterial pressure. On the contrary, gamma(2)-MSH-(6-12) (a fragment unable to bind melanocortin receptors) was ineffective. Such protective effect was prevented by the melanocortin MC(3)/MC(4) receptor antagonist SHU 9119. In normal (i.e., not subjected to myocardial ischemia/reperfusion) rats, the same i.v. dose (162 nmol/kg) of gamma(2)-MSH, [D-Trp(8)]gamma(2)-MSH and gamma(2)-MSH-(6-12) provoked a prompt and transient increase in arterial pressure; on the other hand, ACTH-(1-24), which lacks the C-terminal Arg-Phe sequence, decreased arterial pressure, but only at higher doses. Heart rate of normal rats was not affected by any of the assayed peptides. The present data confirm and extend our previous findings that melanocortins prevent myocardial reperfusion injury by activating melanocortin MC(3) receptors. Moreover, they further support the notion that, in normal rats, cardiovascular effects of gamma-MSHs are mediated by receptors for FMRFamide-like peptides, for whose activation, but not for that of melanocortin MC(3) receptors, the C-terminal Arg-Phe structure being relevant.
- Published
- 2003
- Full Text
- View/download PDF
42. Efferent vagal fibre stimulation blunts nuclear factor-kappaB activation and protects against hypovolemic hemorrhagic shock.
- Author
-
Guarini S, Altavilla D, Cainazzo MM, Giuliani D, Bigiani A, Marini H, Squadrito G, Minutoli L, Bertolini A, Marini R, Adamo EB, Venuti FS, and Squadrito F
- Subjects
- Animals, Blood Pressure, Efferent Pathways, Electric Stimulation, Hypovolemia immunology, Hypovolemia metabolism, Hypovolemia physiopathology, I-kappa B Proteins metabolism, Inflammation genetics, Inflammation metabolism, Inflammation prevention & control, Liver innervation, Liver metabolism, Male, NF-KappaB Inhibitor alpha, Nerve Fibers physiology, RNA, Messenger metabolism, Rats, Rats, Wistar, Shock, Hemorrhagic immunology, Shock, Hemorrhagic metabolism, Survival Analysis, Tumor Necrosis Factor-alpha analysis, Tumor Necrosis Factor-alpha biosynthesis, Tumor Necrosis Factor-alpha genetics, NF-kappa B antagonists & inhibitors, Shock, Hemorrhagic prevention & control, Vagus Nerve physiology
- Abstract
Background: We investigated whether electrical stimulation (STIM) of efferent vagus nerves may suppress nuclear factor (NF)-kappaB activation and the inflammatory cascade in hemorrhagic (Hem) shock., Methods and Results: Rats were subjected to bilateral cervical vagotomy (VGX) or sham surgical procedures. Hem shock was induced by intermittent withdrawing of blood until mean arterial pressure stabilized within the range of 35 to 40 mm Hg. Application of constant voltage pulses to the caudal vagus ends (STIM; 5 V, 2 ms, 1 Hz for 12 minutes, 5 minutes after mean arterial pressure stabilization) increased survival time (VGX+Hem+Sham STIM=38+/-3 minutes; VGX+Hem+STIM >180 minutes), reverted the marked hypotension (VGX+Hem+Sham STIM=33+/-3 mm Hg; VGX+Hem+STIM=66+/-5 mm Hg), inhibited IkappaBalpha liver loss, and blunted the augmented NF-kappaB activity, decreased hepatic tumor necrosis factor (TNF)-alpha mRNA (VGX+Hem+Sham STIM=1.42+/-0.5 amount of TNF-alpha m-RNA; VGX+Hem+STIM=0.51+/-0.2 amount of TNF-alpha mRNA), and reduced plasma TNF-alpha (VGX+Hem+Sham STIM=190+/-24 pg/mL; VGX+Hem+STIM=87+/-15 pg/mL). Chlorisondamine, a nicotinic receptor antagonist, abated the effects of vagal stimulation., Conclusions: Our results show a parasympathetic inhibition of NF-kappaB by which the brain opposes NF-kappaB activation in the liver and modulates the inflammatory response during acute hypovolemic hemorrhagic shock.
- Published
- 2003
- Full Text
- View/download PDF
43. Cannabinoid CB(1) receptor blockade enhances the protective effect of melanocortins in hemorrhagic shock in the rat.
- Author
-
Cainazzo MM, Ferrazza G, Mioni C, Bazzani C, Bertolini A, and Guarini S
- Subjects
- Animals, Blood Pressure drug effects, Cannabinoid Receptor Modulators, Dose-Response Relationship, Drug, Female, Male, Piperidines pharmacology, Pulse, Pyrazoles pharmacology, Rats, Rats, Wistar, Receptors, Cannabinoid, Receptors, Drug physiology, Respiration drug effects, Rimonabant, Shock, Hemorrhagic mortality, Shock, Hemorrhagic physiopathology, Survival Rate, Cosyntropin pharmacology, Receptors, Drug antagonists & inhibitors, Shock, Hemorrhagic prevention & control
- Abstract
Activation of peripheral cannabinoid CB(1) receptors contributes to hemorrhagic hypotension, and endocannabinoids produced by macrophages and platelets may be mediators of this effect. A number of studies have provided evidence that functional links exist in the mechanisms of action of cannabinoids and opioid peptides; and opioids too play an important role in the pathophysiology of hemorrhagic hypotension and shock. On the other hand, melanocortin peptides, which are the main endogenous functional antagonists of opioid peptides, have an antishock effect in animals and humans. Thus, we investigated whether an interaction exists between endocannabinoids and the endogenous opioid/antiopioid system also in a condition of hemorrhagic shock and, particularly, whether the blockade of cannabinoid CB(1) receptors potentiates the antishock effect of melanocortins. Urethane-anesthetized rats were stepwise bled until mean arterial pressure decreased to, and stabilized at, 21-23 mm Hg. In this model of hemorrhagic shock, which caused the death of all control rats within 30 min after vehicle (tween 80, 5% in saline) injection, the intravenous (i.v.) bolus injection of the cannabinoid CB(1) receptor antagonist N-piperidino-5-[4-chlorophenyl]-1-[2,4 dichlorophenyl]-4-methyl-3-pyrazolecarboxamide (SR141716A) increased mean arterial pressure, pulse pressure, respiratory rate and survival rate in a dose-related manner (0.1-3 mg/kg), an almost complete recovery of mean arterial pressure, pulse pressure and respiratory rate, and 100% survival at the end of the observation period (2 h), occurring with the dose of 3 mg/kg. The melanocortin ACTH-(1-24) (adrenocorticotropin) also produced in a dose-related manner (0.02-0.16 mg/kg i.v.) a restoration of cardiovascular and respiratory functions, and increased survival rate, an almost complete recovery and 100% survival at the end of the observation period (2 h) occurring with the dose of 0.16 mg/kg. When a subactive dose of SR141716A (0.2 mg/kg; 30% survival) was associated with a subactive dose of ACTH-(1-24) (0.02 mg/kg; 12% survival), a complete reversal of the shock condition was obtained with 100% survival at the end of the 2-h observation period. The present results show that the concurrent inhibition of both endogenous opioid and cannabinoid systems produces a reversal of hemorrhagic shock more effective than that produced by the inhibition of either of them. These data suggest that functional interactions between endocannabinoids and opioid/antiopioid are at work also in the pathophysiology of hemorrhagic shock.
- Published
- 2002
- Full Text
- View/download PDF
44. Involvement of the central nervous system in the protective effect of melanocortins in myocardial ischaemia/reperfusion injury.
- Author
-
Bazzani C, Mioni C, Ferrazza G, Cainazzo MM, Bertolini A, and Guarini S
- Subjects
- Animals, Disease Models, Animal, Dose-Response Relationship, Drug, Female, Injections, Intravenous, Injections, Intraventricular, Lidocaine pharmacology, Male, Myocardial Ischemia drug therapy, Myocardial Ischemia mortality, Myocardial Reperfusion Injury metabolism, Myocardial Reperfusion Injury mortality, Probability, Rats, Rats, Wistar, Reference Values, Sensitivity and Specificity, Sodium Chloride pharmacology, Survival Analysis, Adrenocorticotropic Hormone pharmacology, Central Nervous System drug effects, Myocardial Ischemia prevention & control, Myocardial Reperfusion Injury prevention & control
- Abstract
Melanocortin peptides exert, in rats, a protective effect in myocardial ischaemia followed by reperfusion, or permanent occlusion of a coronary artery. Moreover, melanocortins have an anti-shock effect. Since the mechanism of the life-saving effect of these peptides in haemorrhagic shock includes an essential brain loop, we aimed to determine whether the central nervous system (CNS) is also involved in the protective effect against the outcome of short-term myocardial ischaemia followed by reperfusion. Ischaemia was produced in anaesthetized rats by ligature of the left anterior descending coronary artery for 5 min. Reperfusion-induced ventricular tachycardia (VT), ventricular fibrillation (VF) and lethality, and the time-course of arterial blood pressure over 5 min following reperfusion were evaluated. Groups of 8-14 rats were used. Intravenous (i.v.) injection of ACTH-(1-24) (0.16-0.48 mg/kg) during the ischaemic period dose dependently reduced the incidence of VT, VF and of lethality. In saline-treated rats, coronary reperfusion caused VT in 100% animals, VF in 86%, and death in 86%. The highest dose of ACTH-(1-24) (0.48 mg/kg) completely prevented the occurrence of VT, VF and death in all rats (P<0.005). Moreover, the melanocortin peptide prevented the fall in mean arterial pressure (MAP) occurring during reperfusion. Treatment with ACTH-(1-24) by the intracerebroventricular (i.c.v.) route also reduced the incidence of VT, VF and lethality, and prevented the fall in MAP in a dose dependent manner. Complete (100%) protection occurred with an i.c.v. dose (0.048 mg/kg) 10 times less than that needed by the i.v. route. The present data show that in the protective effect of melanocortin peptides against the injury after myocardial ischaemia/reperfusion, the i.c.v. route of administration is more effective than the i.v. route. They suggest that a CNS mechanism, not yet identified, may be involved.
- Published
- 2002
- Full Text
- View/download PDF
45. Protective effect of melanocortin peptides in rat myocardial ischemia.
- Author
-
Bazzani C, Guarini S, Botticelli AR, Zaffe D, Tomasi A, Bini A, Cainazzo MM, Ferrazza G, Mioni C, and Bertolini A
- Subjects
- Animals, Arrhythmias, Cardiac prevention & control, Coronary Disease metabolism, Dose-Response Relationship, Drug, Drug Administration Schedule, Electrocardiography drug effects, Electron Spin Resonance Spectroscopy, Female, Free Radicals antagonists & inhibitors, Free Radicals blood, Injections, Intravenous, Injections, Subcutaneous, Male, Myocardial Ischemia metabolism, Myocardial Ischemia pathology, Myocardial Reperfusion, Rats, Rats, Wistar, Reperfusion Injury metabolism, Reperfusion Injury prevention & control, Survival Rate, alpha-MSH analogs & derivatives, Coronary Disease drug therapy, Cosyntropin administration & dosage, Myocardial Ischemia drug therapy, Neuropeptides administration & dosage, alpha-MSH administration & dosage
- Abstract
The influence of the melanocortin peptide ACTH-(1-24) (adrenocorticotropin) on the consequences of short-term coronary ischemia (5 min) followed by reperfusion, and the effect of the long-acting melanocortin [Nle(4),D-Phe(7)]alpha-melanocyte-stimulating hormone (NDP-MSH) on the damage induced by a permanent coronary occlusion, were investigated in anesthetized rats. Ischemia was produced by ligature of the left anterior descending coronary artery. Reperfusion-induced arrhythmias [ventricular tachycardia (VT), ventricular fibrillation (VF)] and survival rate within the 5 min following reperfusion, blood levels of free radicals detected 2 min after reperfusion by electron spin resonance spectrometry, and amount of healthy myocardial tissue, measured 72 h after permanent coronary occlusion on immunohistologically stained serial sections, were evaluated. Postischemic reperfusion induced VT in all saline-treated rats, and VF and death in a high percentage of animals (87%). In rats treated i.v. (2.5 min after coronary occlusion) with ACTH-(1-24) (0.16-0.48 mg/kg) there was a significantly dose-dependent reduction in the incidence of arrhythmias and lethality. Ischemia/reperfusion caused a large increase in free radical blood levels; treatment with ACTH-(1-24) (0.48 mg/kg i.v.) almost completely prevented this increase. In rats subjected to permanent coronary occlusion, the amount of healthy myocardial tissue was much reduced in saline-treated rats, while in rats treated s.c. with NDP-MSH (0.27 mg/kg every 12 h) it was significantly higher. The present data demonstrate, for the first time, an unforeseen property of melanocortin peptides, i.e., their ability to significantly reduce both heart ischemia/reperfusion injury and size of the ischemic area induced by permanent coronary occlusion.
- Published
- 2001
46. Adrenocorticotropin inhibits nitric oxide synthase II mRNA expression in rat macrophages.
- Author
-
Altavilla D, Bazzani C, Squadrito F, Cainazzo MM, Mioni C, Bertolini A, and Guarini S
- Subjects
- Animals, Autoradiography, Depression, Chemical, Female, In Vitro Techniques, Lipopolysaccharides pharmacology, Macrophages, Peritoneal drug effects, Male, Melanocyte-Stimulating Hormones pharmacology, Nitric Oxide biosynthesis, Nitric Oxide Synthase Type II, Rats, Rats, Wistar, Reverse Transcriptase Polymerase Chain Reaction, Adrenocorticotropic Hormone pharmacology, Macrophages, Peritoneal metabolism, Nitric Oxide Synthase biosynthesis, RNA, Messenger biosynthesis
- Abstract
During hemorrhagic shock there is a massive overproduction of nitric oxide (NO). In such conditions, the intravenous (i.v.) injection of melanocortin peptides in nanomolar amounts produces a long-lasting restoration of cardiovascular and respiratory functions associated with the normalization of NO blood levels. To clarify the mechanism of such melanocortin-induced inhibition of NO overproduction, the influence of the adrenocorticotropin fragment 1-24 [ACTH-(1-24)] on the NO synthesizing activity of rat macrophages was studied in vitro. Nitrite production, an indicator of NO synthesis, was measured in the supernatant of rat macrophages whose inducible NO synthase (NOS II, iNOS) had been stimulated by the addition of S. enteritidis lipopolysaccharide (LPS, 50 microg/ml). ACTH-(1-24) (25, 50 and 100 nM) inhibited nitrite production when incubated together with LPS, but had no effect when applied 6 h after LPS. Further, the effect of ACTH-(1-24) on the expression of iNOS mRNA in rat macrophages activated with LPS was studied by means of a reverse transcriptase-polymerase chain reaction assay. ACTH-(1-24) (25, 50 and 100 nM), applied together with LPS, dose-dependently suppressed iNOS gene activation. The present data suggest that the melanocortin-induced normalization of NO blood levels during hemorrhagic shock is due, at least in part, to a direct inhibition of iNOS induction, at the level of mRNA transcription.
- Published
- 2000
- Full Text
- View/download PDF
47. Evidence that melanocortin 4 receptor mediates hemorrhagic shock reversal caused by melanocortin peptides.
- Author
-
Guarini S, Bazzani C, Cainazzo MM, Mioni C, Ferrazza G, Vergoni AV, Schiöth HB, Wikberg JE, and Bertolini A
- Subjects
- Animals, Blood Pressure drug effects, Blood Pressure physiology, Blood Volume physiology, Brain Chemistry drug effects, Cosyntropin pharmacology, Female, Heart Rate drug effects, Heart Rate physiology, Male, Peptides therapeutic use, Rats, Rats, Wistar, Receptor, Melanocortin, Type 4, Receptors, Corticotropin drug effects, Respiratory Mechanics drug effects, Shock, Hemorrhagic physiopathology, Melanocyte-Stimulating Hormones therapeutic use, Receptors, Corticotropin physiology, Shock, Hemorrhagic drug therapy
- Abstract
Melanocortin peptides are known to be extremely potent in causing the sustained reversal of different shock conditions, both in experimental animals and humans; the mechanism of action includes an essential brain loop. Three melanocortin receptor subtypes are expressed in brain tissue: MC(3), MC(4,) and MC(5) receptors. In a volume-controlled model of hemorrhagic shock in anesthetized rats, invariably causing the death of control animals within 30 min after saline injection, the i.v. bolus administration of the adrenocorticotropin fragment 1-24 (agonist at MC(4) and MC(5) receptors) at a dose of 160 microg/kg i.v. (54 nmol/kg) produced an almost complete and sustained restoration of cardiovascular and respiratory functions. An equimolar dose of gamma(1)-melanocyte stimulating hormone (selective agonist at MC(3) receptors) was completely ineffective. The selective antagonist at MC(4) receptors, HS014, although having no influence on cardiovascular and respiratory functions per se, dose-dependently prevented the antishock activity of adrenocorticotropin fragment 1-24, with the effect being complete either at the i.v. dose of 200 microg/kg or at the i.c.v. dose of 5 microg/rat (17-20 microg/kg). We concluded that the effect of melanocortin peptides in hemorrhagic shock is mediated by the MC(4) receptors in the brain.
- Published
- 1999
48. Adrenocorticotropin reverses vascular dysfunction and protects against splanchnic artery occlusion shock.
- Author
-
Squadrito F, Guarini S, Altavilla D, Squadrito G, Campo GM, Arlotta M, Quartarone C, Saitta A, Cucinotta D, Bazzani C, Cainazzo MM, Mioni C, Bertolini A, and Caputi AP
- Subjects
- Animals, Blood Pressure drug effects, Constriction, Pathologic, Endothelium, Vascular drug effects, Endothelium, Vascular metabolism, Immunohistochemistry, In Vitro Techniques, Intercellular Adhesion Molecule-1 metabolism, Male, Rats, Rats, Sprague-Dawley, Tumor Necrosis Factor-alpha metabolism, Tumor Necrosis Factor-alpha physiology, Adrenocorticotropic Hormone pharmacology, Splanchnic Circulation drug effects
- Abstract
1. Tumour necrosis factor (TNF-alpha) is involved in the pathogenesis of splanchnic artery occlusion (SAO) shock. On the other hand, inhibition of TNF-alpha is an important component of the mechanism of action of melanocortins in reversing haemorrhagic shock. We therefore investigated the effects of the melanocortin peptide ACTH-(1 - 24) (adrenocorticotropin fragment 1 - 24) on the vascular failure induced by SAO shock. 2. SAO-shocked rats had a decreased survival rate (0% at 4 h of reperfusion, while sham-shocked rats survived for more than 4 h), enhanced serum TNF-alpha concentrations (755+/-81 U ml-1), decreased mean arterial blood pressure, leukopenia, and increased ileal leukocyte accumulation, as revealed by means of myeloperoxidase activity (MPO=9.4+/-1 U g-1 tissue). Moreover, aortic rings from shocked rats showed a marked hyporeactivity to phenylephrine (PE, 1 nM - 10 microM) (Emax and ED50 in shocked rats=7.16 mN mg-1 tissue and 120 nM, respectively; Emax and ED50 in sham-shocked rats=16.31 mN mg-1 tissue and 100 nM, respectively), reduced responsiveness to acetylcholine (ACh, 10 nM-10 microM) (Emax and ED50 in shocked rats=30% relaxation and 520 nM, respectively; Emax and ED50 in sham-shocked rats=82% relaxation and 510 nM, respectively) and increased staining for intercellular adhesion molecule-1 (ICAM-1). 3. ACTH-(1 - 24) [160 microg kg-1 intravenously (i.v.), 5 min after SAO] increased survival rate [SAO+ACTH-(1 - 24)=80% at 4 h of reperfusion], reversed hypotension, reduced serum TNF-alpha (55+/-13 U ml-1), ameliorated leukopenia, reduced ileal MPO (1.2+/-0.2 U g-1 tissue), restored the reactivity to PE, improved the responsiveness to ACh and blunted the enhanced immunostaining for ICAM-1 in the aorta. 4. Adrenalectomy only in part - but not significantly - reduced the ACTH-induced shock reversal, the survival rate of SAO+ACTH-(1 - 24) adrenalectomized rats being 60% at 4 h of reperfusion; and methylprednisolone (80 mg-1 i.v., 5 min after SAO) had a non-significant effect (10% survival) at 4 h of reperfusion. 5. The present data show that melanocortins are effective also in SAO shock, their effect being, at least in part, mediated by reduced production of TNF-alpha. Furthermore, they demonstrate, for the first time, that this inhibition is responsible for the adrenocorticotropin-induced reversal of vascular failure and leukocyte accumulation.
- Published
- 1999
- Full Text
- View/download PDF
49. High blood levels of nitric oxide in rats subjected to prolonged respiratory arrest and their modulation during adrenocorticotropin-induced resuscitation.
- Author
-
Bazzani C, Bini A, Cainazzo MM, Meletti E, Tomasi A, Bertolini A, and Guarini S
- Subjects
- Animals, Blood Pressure drug effects, Blood Pressure physiology, Cardiopulmonary Resuscitation, Electrocardiography, Electron Spin Resonance Spectroscopy, Electrooculography, Enzyme Inhibitors pharmacology, Female, Heart Rate drug effects, Heart Rate physiology, Hemoglobins metabolism, Isothiuronium analogs & derivatives, Isothiuronium pharmacology, Nitric Oxide Synthase antagonists & inhibitors, Nitric Oxide Synthase Type II, Rats, Rats, Wistar, Respiration, Artificial, Adrenocorticotropic Hormone pharmacology, Nitric Oxide blood, Respiratory Insufficiency physiopathology
- Abstract
Anaesthetized rats, endotracheally intubated and mechanically ventilated with room air, were subjected to a 5-min period of asphyxia by turning off the ventilator. The ventilator was then turned back on and, simultaneously, the animals were treated with either the adrenocorticotropin fragment 1-24 [ACTH-(1-24), 160 microg/kg in a volume of 1 ml/kg i.v.] or an equivalent volume of saline. Nitric oxide (NO)-haemoglobin formation was detected ex vivo in arterial blood by electron spin resonance spectrometry; arterial blood pressure, electrocardiogram (ECG) and electroencephalogram (EEG) were monitored for a 60-min observation period, or until prior death. During asphyxia, there was massive formation of NO (red cell concentrations 40-80 microM), associated with a dramatic fall in mean arterial pressure and pulse pressure, marked bradycardia and ECG signs of ischaemic damage, as well as an isoelectric EEG. Treatment with ACTH-(1-24) produced a prompt (within 15 min) and long-lasting drop in NO blood levels, associated with an almost immediate (within 1 min) restoration of cardiovascular function and with a more gradual recovery of EEG, which became normal after 3040 min; all parameters remained stable throughout the 60-min observation period. In saline-treated rats, on the other hand, there was a further increase in NO blood levels, as detected 3 min after treatment, and all died within 5-8 min. Moreover, pretreatment and treatment with S-methylisothiourea sulphate (SMT, 3 mg/kg i.v.), a relatively specific inhibitor of inducible NO synthase, inhibited NO formation, but did not affect the mortality rate (100% within 5-8 min). The present results provide the first evidence that prolonged asphyxia is associated with high blood concentrations of NO, and that the life-saving effect of melanocortin peptides in severe hypoxic conditions is associated with a complete normalization of NO blood levels. However, the lack of SMT protection in this experimental model seems to rule out the possibility that the ACTH-(1-24)-induced resuscitation is due to an effect on NO overproduction.
- Published
- 1999
- Full Text
- View/download PDF
50. Tumour necrosis factor-alpha as a target of melanocortins in haemorrhagic shock, in the anaesthetized rat.
- Author
-
Altavilla D, Cainazzo MM, Squadrito F, Guarini S, Bertolini A, and Bazzani C
- Subjects
- Anesthesia, Animals, Blood Pressure drug effects, Depression, Chemical, Dose-Response Relationship, Drug, Female, Heart Rate drug effects, Male, Rats, Rats, Wistar, Respiratory Mechanics drug effects, Shock, Hemorrhagic metabolism, Cosyntropin pharmacology, Shock, Hemorrhagic physiopathology, Tumor Necrosis Factor-alpha biosynthesis
- Abstract
The cytokine tumour necrosis factor-alpha (TNF-alpha) is involved (mostly through the activation of inducible nitric oxide synthase) in the pathogenesis of circulatory shock. On the other hand, melanocortin peptides are potent and effective in reversing haemorrhagic shock, both in animals (rat, dog) and in humans. This prompted us to study the influence of the melanocortin peptide ACTH-(1-24) on the blood levels of TNF-alpha in haemorrhage-shocked rats and on the in vitro production of TNF-alpha by lipopolysaccharide (LPS)-activated macrophages. Plasma levels of TNF-alpha were undetectable before starting bleeding and greatly increased 20 min after bleeding termination in saline-treated rats. In rats treated with ACTH-(1-24) the almost complete restoration of cardiovascular function was associated with markedly reduced levels of TNF-alpha 20 min after bleeding termination. On the other hand, ACTH-(1-24) did not influence TNF-alpha plasma levels in sham-operated, unbled rats. In vitro, ACTH-(1-24) (25-100 nM) dose-dependently reduced the LPS-stimulated production of TNF-alpha by peritoneal macrophages harvested from untreated, unbled rats. These results indicate that inhibition of TNF-alpha overproduction may be an important component of the mechanism of action of melanocortins in reversing haemorrhagic shock.
- Published
- 1998
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.